The treatment of Tourette’s syndrome: current opinions

Bibliography

• FREEMAN RD, FAST DK, BURD L, KERBESHIAN J, ROBERTSON MM, SANDOR P: An international perspective on Tourette syndrome: selected findings from 3,500 individuals in 22 countries. Dev. Med. Child Neurol (2000) 42(7):436–447.
   PubMed Web of Science ®Google Scholar
• •A multi-centre, international database of 3500 children reporting a large set of clinical information.
   Google Scholar
• SINGER HS: Current issues in Tourette syndrome. Mov. Disord. (2000) 15(6):1051–1063.
   PubMedGoogle Scholar
• •A good overall review of the phenom-enology, pathology and treatment of TS.
   Google Scholar
• ROBERTSON MM: Tourette syndrome, associated conditions and the complexities of treatment. Brain (2000) 123(3):425–462.
   PubMed Web of Science ®Google Scholar
• ••An excellent and very detailed summaryparticularly of clinical characteristics and treatment of TS.
   Google Scholar
• PETERSON BS, COHEN DJ: The treatment of Tourette's syndrome: multimodal, developmental intervention. Clin. Psychiatry (1998) 59\(Suppl. 1):62–72.
   Google Scholar
• KOSSOFF EH, SINGER HS: Tourette syndrome: clinical characteristics and current management strategies. Paediatr. Drugs (2001) 3(5):355–363.
   PubMedGoogle Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV-TR). American Psychiatric Press, Inc. (2000).
   Google Scholar
• THE TOURETTE SYNDROME CLASSIFICATION STUDY GROUP: Definitions and classification of tic disorders. Arch. Neurol (1993) 50(10):1013–1016.
   PubMedGoogle Scholar
• SHAPIRO AK, SHAPIRO ES, YOUNG JG, FEINBERG TE: Signs, symptoms, and clinical course. In: Gilles de la Tourette Syndrome. 2nd Edition. Shapiro AK, Shapiro ES, Young JG, Feinberg TE (eds), Raven Press, New York, NY, USA (1988):127–193.
   Google Scholar
• HARCHERIK DF, LECKMAN JF, DETLOR J, COHEN DJ: A new instrument for clinical studies of Tourette's syndrome. Am. I Acad. Child Psychiatry (1984) 23(2):153–160.
   PubMedGoogle Scholar
• GOETZ CG, TANNER CM, WILSON RS, SHANNON KM: A rating scale for Gilles de la Tourette's syndrome: description, reliability, and validity data. Neurology (1987) 37(9):1542–1544.
   PubMedGoogle Scholar
• LECKMAN JF, TOWBIN KE, ORT SI, COHEN DJ: Clinical assessment of tic disorder severity. In: Tourette's Syndrome and Tic Disorders. Cohen DJ, Bruun RD, Leckman JF (eds), Wiley, New York, NY, USA (1988):55–78.
   Google Scholar
• SINGER HS: Neurobiology of Tourette syndrome. Neurol Chit. (1998) 15(2):357–379.
   Google Scholar
• MINK JM: Neurobiology of basal ganglia circuit in Tourette Syndrome: faulty inhibition of unwanted motor patterns? Adv. Neurol (2001) 85:113–122.
   Google Scholar
• SINGER HS, WENDTLANDT JT: Neurochemistry and synaptic neurotransmission in Tourette Syndrome. Adv. Neurol (2001) 85:163–178.
   PubMedGoogle Scholar
• MOLLER-VAHL KR, KOLBE H, SCHNEIDER U, EMRICH HM: Cannabinoids: Possible role in pathophysiology of Gilles de la Tourette syndrome. Acta. Psychiat. Scand. (1998) 98(6):502–506.
   PubMedGoogle Scholar
• PAULS DL: Update on the genetics of Tourette syndrome. Adv. Neurol (2001) 85:281–293.
   PubMedGoogle Scholar
• SEIGNOT MJN: Un cas de maladie des tics de Gilles de la Tourette gueri par le R-1625. Ann. Med. Psychiatry (1961) 119:578–579.
   Google Scholar
• CAPRINI G, MELOTTI V: Un grave syndrome ticcosa guarta con haloperidol. Riv. Sper. Freniat. (1961) 85:191–196.
   Google Scholar
• ABUZZAHAB FE SR, ANDERSON FO: Gilles de la Tourette's syndrome; international registry. Minn. Med. (1973) 56(6):492–496.
   PubMedGoogle Scholar
• SHAPIRO AK, SHAPIRO E, WAYNE H: Treatment of Tourette's syndrome with haloperidol, review of 34 cases. Arch. Gen. Psychiatry (1973) 28(1):92–97.
   PubMed Web of Science ®Google Scholar
• CONNELL PH, CORBETT JA, HORNE DJ, MATHEWS AM: Drug treatment of adolescent tiqueurs. A double-blind trial of diazepam and haloperidol. Br. j Psychiatry (1967) 113(497):375–381.
   PubMedGoogle Scholar
• SHAPIRO E, SHAPIRO AK, FULOP G et al.: Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch. Gen. Psychiatry (1989) 46(8):722–730.
   PubMed Web of Science ®Google Scholar
• •A well-designed study in 57 patients demonstrating that both haloperidol and pimozide are effective in the treatment of TS.
   Google Scholar
• ROSS MS, MOLDOFSKY H: A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette's syndrome. Am. I Psychiatry (1978) 135(5):585–587.
   PubMed Web of Science ®Google Scholar
• SANDOR P, MUSISI S, MOLDOFSKY H, LANG A: Tourette syndrome: a follow-up study. j Clin. Psychopharmacol (1990) 10(3):197–199.
   PubMed Web of Science ®Google Scholar
• SALLEE FR, NESBITT L, JACKSON C, SINE L, SETHURAMAN G: Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am. J. Psychiatry (1997) 154(8):1057–1062.
   PubMed Web of Science ®Google Scholar
• •A controlled study suggesting that pimozide is superior to haloperidol in the •• treatment of TS.
   Google Scholar
• SHAPIRO AK, SHAPIRO E, EISENKRAFT GJ: Treatment of Gilles de la Tourette syndrome with pimozide. Am.). Psychiatry (1983) 140(9):1183–1186.
   PubMed Web of Science ®Google Scholar
• SHAPIRO AK, SHAPIRO E, BRUUN RD, SWEET RD: Gilles de la Tourette Syndrome. Shapiro AK, Shapiro ES, Young JG, Feinberg TE (eds), Raven Press, New York, NY, USA (1978).
   Google Scholar
• ••This first comprehensive review of TS is ofhistorical importance.
   Google Scholar
• FULTON WA: Intermittent medication cessation in the treatment of Tourette syndrome. Neurosci. Biobehav. Rev (1988) 12(3-4):235–240.
   PubMed Web of Science ®Google Scholar
• SILVA RR, MUNOZ DM, DANIEL W, BARICKMAN J, FRIEDHOFF AJ: Causes of haloperidol discontinuation in patients with Tourette's disorder: management and alternatives. Clin. Psychiatry (1996) 57(3):129–135.
   PubMed Web of Science ®Google Scholar
• DEBRAY P, MESSERSCHMITT P, LONCHAMP D, HERBAULT M: L'utilization du pimozide en pedopsychiatrie. Nouv. Presse. Med. (1972) 1(43):2917–2918.
   PubMedGoogle Scholar
• SHAPIRO AK, SHAPIRO E: Controlled study of pimozide versus placebo in Tourette's syndrome. I Am. Acad. Child. Psychiatry (1984) 23(2):161–173.
   Google Scholar
• REGEUR L, PAKKENBERG B, FOG R, PAKKENBERG H: Clinical features and long-term treatment with pimozide in 65 patients with Gilles de la Tourette's syndrome. J. Neurol Neurosurg. Psychiatry (1986) 49(7):791–795.
   PubMed Web of Science ®Google Scholar
• TOURETTE SYNDROME STUDY GROUP: Short-term versus longer term pimozide therapy in Tourette's syndrome: a preliminary study. Neurology (1999) 52(4):874–877.
   PubMedGoogle Scholar
• •This is the only available study assessing the efficacy of short- versus long-term therapy with pimozide. According to this pilot study long-term treatment has a more favourable influence on the course of tics than a short-term course.
   Google Scholar
• SALLEE FR, POLLOCK BG, STILLER RL, STULL S, EVERETT G, PEREL JM: Pharmacokinetics of pimozide in adults and children with Tourette's syndrome. I Gin. Pharmacol (1987) 27(10):776–781.
   Google Scholar
• FULOP G, PHILLIPS RA, SHAPIRO AK, GOMES JA, SHAPIRO E, NORDLIE JVV: ECG changes during haloperidol and pimozide treatment of Tourette's disorder. Am.Psychiatry (1987) 144(5):673–675.
   PubMed Web of Science ®Google Scholar
• SHAPIRO AK, SHAPIRO E, FULOP G: Pimozide treatment of tic and Tourette disorders. Pediatrics (1987) 79(6):1032–1039.
   PubMed Web of Science ®Google Scholar
• YVONNEAU M, BEZARD P: Sur un cas de maladie des tics bloquee par ir sulpiride. Ètude psycho-biologique. Encephak (1970) 59(5):439–459.
   PubMedGoogle Scholar
• ROBERTSON MM, SCHNIEDEN V, LEES AJ: Management of Gilles de la Tourette syndrome using sulpiride. Clin. Neuropharmacol (1990) 13(3):229–235.
   PubMed Web of Science ®Google Scholar
• GEORGE MS, TRIMBLE MR, ROBERTSON MM: Fluvoxamine and sulpiride in combined obsessive-compulsive disorder and Gilles de la Tourette syndrome. Hum. Psychopharmacol (1993) 8:327–334.
   Web of Science ®Google Scholar
• LIPCSEY A: Gilles de la Tourette's disease.Sem. Hop. (1983) 59(10):695–696.
   Google Scholar
• KLEPEL H, GEBELT H, KOCH RD, TZENOW H: Treatment of extrapyramidal hyperkineses in childhood with tiapride. Psychiatr. Neurol Med. Psycho]. (Leipz) (1988) 40(9):516–522.
   PubMedGoogle Scholar
• EGGERS C, ROTHENBERGER A, BERGHAUS U: Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur. Arch. Psychiatry Neurol Sci. (1988) 237(4):223–229.
   PubMedGoogle Scholar
• CHOUZA C, ROMERO S, LORENZO J et al.: Clinical trial of tiapride in patients with dyskinesia. Sem. Hop. (1982) 58(12):725–733.
   PubMedGoogle Scholar
• SUMIYOSHI T, KIDO H, SAKAMOTO H et al.: In vivo dopamine D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol. Pharmacol Biochem. Behav. (1994) 47(3):553–557.
   PubMedGoogle Scholar
• STAMENKOVIC M, ASCHAUER H, KASPER S: Risperidone for Tourette's syndrome. Lancet (1994) 344(8936):1577–1578.
   PubMedGoogle Scholar
• VAN DER LINDEN C, BRUGGEMAN R, VAN WOERKOM TC: Serotonin-dopamine antagonist and Gilles de la Tourette's syndrome: an open pilot dose-titration study with risperidone. Mov. Disord. (1994) 9(6):687–688.
   PubMedGoogle Scholar
• SHULMAN LM, SINGER C, WEINER WJ: Risperidone in Gilles de la Tourette syndrome. Neurology (1995) 45(7):1419.
   PubMed Web of Science ®Google Scholar
• LOMBROSO PJ, SCAHILL L, KING RA et al.: Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. I Am. Acad. Child. Adolesc. Psychiatry (1995) 34(9):1147–1152.
   PubMed Web of Science ®Google Scholar
• BRUUN RD, BUDMAN CL: Risperidone as a treatment for Tourette's syndrome. J. Gin. Psychiatry (1996) 57(1):29–31.
   Google Scholar
• SAND OR P, STEPHENS RJ: Risperidone treatment of aggressive behavior in children with Tourette syndrome. j. Clin. Psychopharmacol (2000) 20(6):710–712.
   Google Scholar
• BRUGGEMAN R, VAN DER LINDEN C, BUITELAARJK, GERICKE GS, HAWKRIDGE SM, TEMLETT JA: Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. I Gin. Psychiatry (2001) 62(1):50–56.
   Google Scholar
• •A comparative double-blind study suggesting that risperidone is as efficacious and safe as pimozide in patients with TS.
   Google Scholar
• GAFFNEY GR, PERRY PJ, LUND BC, BEVER-STILLE KA, ARNDT S, KUPERMAN S: Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. Am. Acad. Child. Adolesc. Psychiatry (2002) 41(3):330–336.
   PubMed Web of Science ®Google Scholar
• •According to this controlled study, the efficacy of risperidone is equivalent to that of donidine in the treatment of tics.
   Google Scholar
• DION Y, ANNABLE L, SAND OR P, CHOUINARD G: Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial. I Gin. Psychopharmacol (2002) 22(1):31–39.
   Google Scholar
• •A double-blind, placebo-controlled trial demonstrating that risperidone is superior to placebo in the treatment of TS.
   Google Scholar
• GIAKAS WJ: Risperidone treatment for a Tourette's disorder patient with comorbid obsessive-compulsive disorder. Am. I Psychiatry (1995) 152(7):1097–1098.
   PubMed Web of Science ®Google Scholar
• JACOBSEN FM: Risperidone in the treatment of affective illness and obsessive-compulsive disorder. I Gin. Psychiatry (1995) 56(9):423–429.
   Google Scholar
• SAXENA S, WANG D, BYSTRITSKY A, BAXTER LR JR: Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. Gin. Psychiatry (1996) 57(7):303–306.
   Google Scholar
• STEIN DJ, BOUWER C, HAWKRIDGE S, EMSLEY RA: Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. I Gin. Psychiatry (1997) 58(3):119–122.
   Google Scholar
• FITZGERALD KD, STEWART CM, TAWILE V, ROSENBERG DR: Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder. Child Adolesc. Psychopharmacol. (1999) 9(2):115–123.
   PubMed Web of Science ®Google Scholar
• BUDMAN CL, GAYER A, LESSER M, SHI Q, BRUUN RD: An open-label study of the treatment efficacy of olanzapine for Tourette's disorder. j. Clin. Psychiatry(2001) 62 (4): 290–294.
   PubMed Web of Science ®Google Scholar
• BHADRINATH BR: Olanzapine in Tourette's syndrome. Br. Psychiatry(1998) 172:366.
   PubMed Web of Science ®Google Scholar
• KARAM-HAGE M, GHAZIUDDIN N: Olanzapine in Tourette's disorder. Am. Acad. Child. Adolesc. Psychiatry (2000) 39(2):139.
   PubMed Web of Science ®Google Scholar
• BENGI SEMERCI Z: Olanzapine in Tourette's disorder. j. Am. Acad. Child. Adolesc. Psychiatry (2000) 39(2):140.
   PubMedGoogle Scholar
• STAMENKOVIC M, SCHINDLER SD, ASCHAUER HN et al.: Effective open-label treatment of Tourette's disorder with olanzapine. Int. Gin. Psychopharmacol (2000) 15(1):23–28.
   PubMed Web of Science ®Google Scholar
• ONOFRJ M, PACI C, D'ANDREAMATTE0 G, TOMA L: Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study versus low-dose pimozide. Neurol (2000) 247(6):443–446.
   Google Scholar
• SALLEE FR, KURLAN R, GOETZ CG et al.: Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. I Am. Acad. Child. Adolesc. Psychiatry(2000) 39(3):292–299.
   PubMed Web of Science ®Google Scholar
• •According to this double-blind, placebo-controlled study the new atypical NL ziprasidone is effective and well tolerated in the treatment of tics.
   Google Scholar
• PARRAGA HC, PARRAGA MI, WOODWARD RL, FENNING PA: Quetiapine treatment of children with Tourette's syndrome: report of two cases. Child. Adolesc. Psychopharmacol (2001) 11(2):187–191.
   PubMedGoogle Scholar
• SCHMIDER J, HOFF P: Clozapine in Tourette's syndrome. j Clin. Psychopharmacol (1998) 18(1):88–89.
   PubMed Web of Science ®Google Scholar
• CAINE ED, POLINSKY RJ, KARTZINEL R, EBERT MH: The trial use of clozapine for abnormal involuntary movement disorders. Am. Psychiatry (1979) 136(3):317–320.
   PubMedGoogle Scholar
• SINGER HS, GAMMON K, QUASKEY S: Haloperidol, fluphenazine and clonidine in Tourette syndrome: controversies in treatment. Pediatr. Neurosci. (1985–86) 12(2):71–74.
   Google Scholar
• GOETZ CG, TANNER CM, KLAWANS HL: Fluphenazine and multifocal tic disorders. Arch. Neurol (1984) 41(3):271–272.
   PubMed Web of Science ®Google Scholar
• BORISON RL, ANG L, HAMILTON WJ, DIAMOND BI, DAVIS JM: Treatment approaches in Gilles de la Tourette syndrome. Brain Res. Bull. (1983) 11(2):205–208.
   PubMed Web of Science ®Google Scholar
• DESAI AB, DOONGAJI DR, SATOSKAR RS: Metoclopramide in Gilles de la Tourette's syndrome (a case report). Postgrad. Merl (1983) 29(3):181–183.
   PubMedGoogle Scholar
• TRILLET M, MOREAU T, DALERY J, DE VILLARD R, AIMARD G: Traitement de la maladie de Gilles de la Tourette par l'amisulpride. Presse Med. (1990) 19(4):175.
   PubMedGoogle Scholar
• JANKOVIC J, BEACH J: Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology(1997) 48(2):358–362.
   PubMed Web of Science ®Google Scholar
• JANKOVIC J, GLAZE DG, FROST JD JR: Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome. Neurology (1984) 34(5):688–692.
   PubMed Web of Science ®Google Scholar
• JANKOVIC J, ORMAN J: Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology (1988) 38(3):391–394.
   PubMed Web of Science ®Google Scholar
• FEINBERG M, CARROLL BJ: Effects of dopamine agonists and antagonists in Tourette's disease. Arch. Gen. Psychiatry (1979) 36(9):979–985.
   PubMedGoogle Scholar
• LIPINSKI JF, SALLEE FR, JACKSON C,SETHURAMAN G: Dopamine agonist treatment of Tourette disorder in children: results of an open-label trial of pergolide. Mov. Disord (1997) 12(3):402–407.
   PubMedGoogle Scholar
• GILBERT DL, SETHURAMAN G, SINE L, PETERS S, SALLEE FR: Tourette's syndrome improvement with pergolide in a randomized, double-blind, crossover trial. Neurology (2000) 54(6):1310–1315.
   PubMedGoogle Scholar
• •A double-blind, crossover trial suggesting that the dopamine agonist pergolide is effective and safe in the treatment of TS.
   Google Scholar
• BLACK KJ, MINK JVV: Response to levodopa challenge in Tourette syndrome. Mov. Disord (2000) 15(6):1194–1198.
   PubMedGoogle Scholar
• GRIESEMER DA: Pergolide in the management of Tourette syndrome. Child. Neurol (1997) 12(6):402–403.
   Google Scholar
• GOETZ CG, STEBBINS GT, THELEN JA: Talipexole and adult Gilles de la Tourette's syndrome: double-blind, placebo- controlled clinical trial. Mov. Disord. (1994) 9(3):315–317.
   PubMedGoogle Scholar
• BRAUN A, MOURADIAN MM, MOHR E, FABBRINI G, CHASE TN: Selective D1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders. J. NeuroL Neurosurg. Psychiatry(1989) 52(5):631–635.
   PubMedGoogle Scholar
• COHEN DJ, YOUNG JG, NATHANSON JA, SHAYWITZ BA: Clonidine in Tourette's syndrome. Lancet (1979) 2(8142):551–553.
   PubMedGoogle Scholar
• COHEN DJ, DETLOR J, YOUNG JG, SHAYWITZ BA: Clonidine ameliorates Gilles de la Tourette syndrome. Arch. Gen. Psychiatry (1980) 37(12):1350–1357.
   PubMed Web of Science ®Google Scholar
• DYSKEN MW, BERECZ JM, SAMARZA A, DAVIS JM: Clonidine in Tourette syndrome. Lancet (1980) 2(8200):926–927.
   PubMedGoogle Scholar
• MCKEITH IG, WILLIAMS A, NICOL AR: Clonidine in Tourette syndrome. Lancet (1981) 1(8214):270–271.
   PubMedGoogle Scholar
• SHAPIRO AK, SHAPIRO E: Clonidine and haloperidol in Gilles de la Tourette syndrome. Arch. Gen. Psychiatry (1981) 38(10):1183–1185.
   PubMedGoogle Scholar
• FERRE RC: Tourette's disorder and the use of clonidine. I Am. Acad. Child. Psychiatry (1982) 21(3):294–297.
   Google Scholar
• SHAPIRO AK, SHAPIRO E, EISENKRAFT GJ: Treatment of Gilles de la Tourette's syndrome with clonidine and neuroleptics. Arch. Gen. Psychiatry(1983) 40(11):1235–1240.
   PubMed Web of Science ®Google Scholar
• LECKMAN JF, DETLOR J, HARCHERIK DF, ORT S, SHAYWITZ BA, COHEN DJ: Short- and long-term treatment of Tourette's syndrome with clonidine: a clinical perspective. Neurology (1985) 35(3):343–351.
   PubMed Web of Science ®Google Scholar
• GOETZ CG, TANNER CM, WILSON RS, CARROLL VS, COMO PG, SHANNON KM: Clonidine and Gilles de la Tourette's syndrome: double-blind study using objective rating methods. Ann. Neurol (1987) 21(3):307–310.
   PubMed Web of Science ®Google Scholar
• •According to this double-blind, placebo-controlled trial, clonidine does not improve tics or behaviour in children or adults with TS.
   Google Scholar
• COMINGS DE, COMINGS BG, TACKET T, LI SZ: The clonidine patch and behavior problems. I Am. Acad. Child. Adolesc. Psychiatry (1990) 29(4):667–668.
   PubMedGoogle Scholar
• GANCHER S, CONANT-NORVILLE D,ANGELL R: Treatment of Tourette's syndrome with transdermal clonidine: a 910 Expert Op/n. Pharmacother. (2002) 3(7) pilot study. I Neuropsychiatry Clin. Neurosci. (1990) 2(1):66–69.
   Google Scholar
• LECKMAN JF, HARDIN MT, RIDDLE MA, STEVENSON J, ORT SI, COHEN DJ: Clonidine treatment of Gilles de la Tourette's syndrome. Arch. Gen. Psychiatry (1991) 48(4):324–328.
   PubMed Web of Science ®Google Scholar
• •In this double-blind, placebo-controlled trial in 47 TS patients clonidine was found to be more effective than placebo in reducing tics and behavioural symptoms.
   Google Scholar
• LICHTER DG, JACKSON LA: Predictors of clonidine response in Tourette syndrome: implications and inferences. I Child. Neurol (1996) 11(2):93–97.
   PubMed Web of Science ®Google Scholar
• BALLDIN J, BERGGREN U, ERIKSSON E, LINDSTEDT G, SUNDKLER A: Guardacine as an oc-2-agonist inducer of growth hormone secretion - a comparison with clonidine. Psychoneumendocrinology (1993) 18(1):45–55.
   PubMed Web of Science ®Google Scholar
• FRAS I: Guardacine for Tourette's disorder. Am. Acad. Child. Adolesc. Psychiatry (1996) 35(1):3–4.
   PubMed Web of Science ®Google Scholar
• CHAPPELL PB, RIDDLE MA, SCAHILL L et al.: Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. I Am. Acad. Child. Adolesc. Psychiatry (1995) 34(9):1140–1146. loft SCAHILL L, CHAPPELL PB, KIM YS et al.: A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am. I Psychiatry (2001) 158(7):1067–1074.
   Google Scholar
• GONCE M, BARBEAU A: Seven cases of Gilles de la Tourette's syndrome: partial relief with clonazepam: a pilot study. Can. Neurol Sci. (1977) 4(4):279–283.
   PubMed Web of Science ®Google Scholar
• KAIM B: A case of Gilles de la Tourette's syndrome treated with clonazepam. Brain Res. Bull. (1983) 11(2):213–214.
   PubMedGoogle Scholar
• TRUONG DD, BRESSMAN S, SHALE H, FAHN S: Clonazepam, haloperidol, and clonidine in tic disorders. South. Med. (1988) 81:1103–1104.
   Google Scholar
• MERIKANGAS JR, MERIKANGAS KR, KOPP U, HANIN I: Blood choline and response to clonazepam and haloperidol in Tourette's syndrome. Acta. Psychiati: Scand. (1985) 72(4):395–399.
   PubMed Web of Science ®Google Scholar
• MONDRUP K, DUPONT E, BRAENDGAARD H: Progabide in the treatment of hyperkinetic extrapyramidal movement disorders. Acta. Neurol Scand. (1985) 72(3):341–343.
   PubMedGoogle Scholar
• STAHL SM, THORNTON JE, SIMPSON ML, BERGER PA, NAPOLIELLO MJ: Gamma-vinyl-GABA treatment of tardive dyskinesia and other movement disorders. Biol. Psychiatry (1985) 20(8):888–893.
   PubMedGoogle Scholar
• AWAAD Y: Tics in Tourette syndrome: new treatment options. Child. NeuroL (1999) 14(5):316–319.
   Google Scholar
• SHAPIRO AK, SHAPIRO ES, YOUNG JG, FEINBERG TE: Studies of treatment. In: Gilles de la Tourette syndrome 2m Edition. Shapiro AK, Shapiro ES, Young JG, Feinberg TE (eds), Raven Press, New York, NY, USA (1988) 381–421. los. SINGER HS, WENDLANDT J, KRIEGER M, GIULIANO J: Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial. Neurology(2001) 56(5):599–604.
   Google Scholar
• •This is the first controlled study of baclofen suggesting that treatment with this GABAergic drug is associated with an improvement in overall impairment scores rather than a reduction of motor and vocal tics.
   Google Scholar
• SANBERG PR, FOGELSON HM, MANDERSCHEID PZ, PARKER KW, NORMAN AB, MCCONVILLE BJ: Nicotine gum and haloperidol in Tourette's syndrome. Lancet (1988) 1(8585):592.
   PubMedGoogle Scholar
• SANBERG PR, MCCONVILLE BJ, FOGELSON HM et al: Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome. Biomed. Pharmacother. (1989) 43(1):19–23.
   PubMedGoogle Scholar
• MCCONVILLE BJ, FOGELSON MH, NORMAN AB et al.: Nicotine potentiation of haloperidol in reducing tic frequency in Tourette's disorder. Am. I Psychiatry (1991) 148(6):793–794.
   PubMedGoogle Scholar
• MCCONVILLE BJ, SANBERG PR, FOGELSON MH et al.: The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder. Biol. Psychiatry(1992) 31(8):832–840.
   PubMedGoogle Scholar
• •Results of this double-blind, placebo-controlled trial suggested that nicotine gum potentiates haloperidol effects in treating TS and shows lesser effects when used alone.
   Google Scholar
• SILVER AA, SANBERG PR: Transdermal nicotine patch and potentiation of haloperidol in Tourette's syndrome. Lancet (1993) 342(8864):182.
   PubMedGoogle Scholar
• DURSUN SM, REVELEY MA, BIRD R, STIRTON F: Longlasting improvement of Tourette's syndrome with transdermal nicotine. Lancet (1994) 344(8936):1577.
   PubMedGoogle Scholar
• DURSUN SM, REVELEY MA: Differential effects of transdermal nicotine on microstructured analyses of tics in Tourette's syndrome: an open study. Psycho]. Med. (1997) 27(2):483–487.
   PubMedGoogle Scholar
• SILVER AA, SHYTLE RD, PHILIPP MK, SANBERG PR: Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette's syndrome. I Am. Acad. Child Adolesc. Psychiatry (1996) 35(12):1631–1636.
   PubMedGoogle Scholar
• SILVER AA, SHYTLE RD, PHILIPP MK, WILKINSON BJ, MCCONVILLE B, SANBERG PR: Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study. I. Clin. Psychiatry (2001) 62(9):707–714.
   PubMedGoogle Scholar
• •According to this controlled study, transdermal nicotine potentiates the effect of neuroleptics in reducing tics. Significant side effects were frequent.
   Google Scholar
• DEVOR EJ, ISENBERG KE: Nicotine and Tourette's syndrome. Lancet (1989) 2(8670):1046.
   PubMedGoogle Scholar
• DIMITSOPULOS T, KURLAN R: Tourette's syndrome and nicotine withdrawal. I. Neuropsychiatry Clin. Neurosci. (1993) 5(1):108–109.
   PubMedGoogle Scholar
• MOLLER-VAHL KR, KOLBE H, DENGLER R: Gilles le laTourette Syndrome: Einflu von Nikotin, Alkohol und Marihuana auf die klinische Symptomatik. Nervenarzt (1997) 68(12):985–989.
   PubMedGoogle Scholar
• LEVIN ED, LIPPIELLO P: Mutually potentiating effects of mecamylamine and haloperidol in producing catalepsy in rats. Drug Dev. Res. (1999) 47:90–96.
   Web of Science ®Google Scholar
• SANBERG PR, SHYTLE RD, SILVER AA: Treatment of Tourette's syndrome with mecamylamine. Lancet (1998) 352(9129):705–706.
   PubMedGoogle Scholar
• SILVER AA, SHYTLE RD, SANBERG PR: Mecamylamine in Tourette's syndrome: a two-year retrospective case study. I Child. Adolesc. Psychopharmacol (2000) 10(2):59–68.
   PubMedGoogle Scholar
• SILVER AA, SHYTLE RD, SHEEHAN KH, SHEEHAN DV, RAMOS A, SANBERG PR: Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's disorder. I Am. Acad. Child Adolesc. Psychiatry (2001) 911 40(9):1103–1110.
   Google Scholar
• •According to this controlled study, and in contrast to anecdotal reports, mecarnylarnine is not effective for tics.
   Google Scholar
• JANKOVIC J: Botulinum toxin in the treatment of dystonic tics. Mov. Disord. (1994) 9(3):347–349.
   PubMedGoogle Scholar
• KWAK CH, HANNA PA, JANKOVIC J: Botulinum toxin in the treatment of tics. Arch. Neurol (2000) 57(8):1190–1193.
   PubMed Web of Science ®Google Scholar
• SALLOWAY S, STEWART CE ISRAELI L et al.: Botulinum toxin for refractory vocal tics. Mov. Disord. (1996) 11(6):746–748.
   Google Scholar
• SCOTT BL, JANKOVIC J, DONOVAN DT: Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome. Mov. Disord (1996) 11(4):431–433.
   PubMedGoogle Scholar
• TRIMBLE MR, WHURR R, BROOKES G, ROBERTSON MM: Vocal tics in Gilles de la Tourette syndrome treated with botulinum toxin injections. Mov. Disord. (1998) 13(3):617–619.
   PubMedGoogle Scholar
• MARRAS C, ANDREWS D, SIME E, LANG AE: Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology (2001) 56(5):605–610.
   PubMed Web of Science ®Google Scholar
• •This is the first controlled study investigating the efficacy of BTX in the treatment of tics. Although a significant decrease in the frequency of treated tics was seen, there was no change in the indices of overall patient well being.
   Google Scholar
• ELSOHLY MA: Chemical constituents of cannabis. In: Cannabis, and Cannabinoids. Pharmacology Toxicology and Therapeutic Potential. Grotenhermen F, Russo E (eds), The Haworth Integrative Healing Press, New York, NY, USA (2002):27–36.
   Google Scholar
• HERKENHAM M, LYNN AB, LITTLE MD et al.: Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA (1990) 87(5):1932–1936.
   PubMed Web of Science ®Google Scholar
• SANDYK R, AWERBUCH G: Marijuana and Tourette's syndrome. j. Clin. Psychopharmacol (1988) 8(6):444–445.
   PubMed Web of Science ®Google Scholar
• HEMMING M, YELL OWLEES PM: Effective treatment of Tourette's syndrome with marijuana. Psychopharmacol (1993) 7(4):389–391.
   Google Scholar
• MOLLER-VAHL KR, SCHNEIDER U, KOLBE H, EMRICH HM:Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol. Am. .1. Psychiatry (1999) 156(3):495.
   Google Scholar
• MOLLER-VAHL KR, KOBLENZ A, JOBGES M, KOLBE H, EMRICH HM, SCHNEIDER U: Influence of delta-9-Tetrahydrocannabinol (49-THC) treatment of Tourette syndrome on neuropsychological testing. Pharmacopsychiaby (2001) 34(1):19–24.
   PubMedGoogle Scholar
• MOLLER-VAHL KR, SCHNEIDER U, THELOE K, PREVEDEL H, KOLBE H, EMRICH HM: Cannabinoids in the treatment of Tourette syndrome. Congress on Cannabis and Cannabinoids, International Association for Cannabis as Medicine, Berlin, Germany (25 October 2001).
   Google Scholar
• MOLLER-VAHL KR, SCHNEIDER U, KOBLENZ A et al.: Treatment of Tourette syndrome with 49-tetrahydrocannabinol (THC). Pharmacopsychiatry (2002) 35(2):57–61.
   PubMedGoogle Scholar
• MOLLER-VAHL KR, PREVEDEL H, THELOE K, KOLBE H, EMRICH HM, SCHNEIDER U: Treatment of Tourette syndrome with 49-Tetrahydrocannabinol (49-THC): no influence on neuro-psychological performance. Neuropsycho-pharmacology (2002). In Press.
   Google Scholar
• MOLLER-VAHL KR, SCHNEIDER U, EMRICH HM: CombinedTreatment of Tourette syndrome with A9-THC and dopamine receptor antagonists. Cannabis Therap. (2002). In Press.
   Google Scholar
• HERMAN BH, HAMMOCK MK, ARTHUR-SMITH A et al.: Naltrexone decreases self-injurious behavior. Ann. Neurol (1987) 22(4):550–552.
   PubMed Web of Science ®Google Scholar
• SANDYK R: Naltrexone suppresses abnormal sexual behavior in Tourette's syndrome. Int. J. Neurosci. (1988) 43(1-2):107–110.
   PubMed Web of Science ®Google Scholar
• ERENBERG G, LEDERMAN RJ: Naltrexone and Tourette's syndrome. Ann. Neurol (1992) 31(5):574.
   PubMedGoogle Scholar
• KURLAN R, MAJUMDAR L, DEELEY C, MUDHOLKAR GS, PLUMB S, COMO PG: A controlled trial of propoxyphene and naltrexone in patients with Tourette's syndrome. Ann. Neurol (1991) 30(1):19–23.
   PubMed Web of Science ®Google Scholar
• •According to this controlled trial the opiate receptor antagonist naltrexone produces only a mild improvement in tic severity.
   Google Scholar
• SANDYK R: The effects of naloxone in Tourette's syndrome. Ann. Neurol (1985) 18(3):367–368.
   PubMedGoogle Scholar
• SANDYK R: Naloxone withdrawal exacerbates Tourette syndrome. Clin. Psychopharmacol (1986) 6(1):58–59.
   PubMedGoogle Scholar
• SANDYK R: Naloxone abolishes obsessive-compulsive behavior in Tourette's syndrome. Int. NeuroscL (1987) 35(1–2)93–94.
   Google Scholar
• GADOTH N, GORDON CR, STREIFLER J: Naloxone in Gilles de la Tourette's syndrome. Ann. Neurol (1987) 21(4):415.
   PubMedGoogle Scholar
• CHAPPELL PB, LECKMAN JF, RIDDLE MA et al: Neuroendocrine and behavioral effects of naloxone in Tourette syndrome. Adv. Neurol (1992) 58:253–262.
   PubMedGoogle Scholar
• VAN WATTUM PJ, CHAPPELL PB, ZELTERMAN D, SCAHILL LD, LECKMAN JF: Patterns of response to acute naloxone infusion in Tourette's syndrome. Mov. Disord. (2000) 15(6):1252–1254.
   PubMedGoogle Scholar
• SANDYK R: Tourette syndrome: successful treatment with clonidine and oxycodone. Neurol (1986) 233(3):178–179.
   Google Scholar
• LICHTER D, MAJUMDAR L, KURLAN R: Opiate withdrawal unmasks Tourette's syndrome. Clin. Neuropharmacol (1988) 11(6):559–564.
   PubMedGoogle Scholar
• SANDYK R, AWERBUCH G: Recurrence of complex motor and vocal tics in an elderly woman responsive to opiates. Int. .1. Neurosci. (1989) 44(3–4):317–320.
   Google Scholar
• WALTERS AS, HENING W, CHOKROVERTY S: Opioid therapy in the movement disorders. Mov. Disord. (1990) 5(1):89–90.
   PubMedGoogle Scholar
• BRUUN R, KURLAN R: Opiate therapy and self-harming behavior in Tourette's syndrome. Mov. Disord. (1991) 6(2):184–185.
   PubMedGoogle Scholar
• MEULDIJK R, COLON EJ: Methadone treatment of Tourette's disorder. Am. .1. Psychiatry (1992) 149(1):139–140.
   Google Scholar
• SHAPIRA NA, MCCONVILLE BJ, PAGNUCCO ML, NORMAN AB, KECK PE JR: Novel use of tramadol hydrochloride in the treatment of Tourette's syndrome. Clin. Psychiatry (1997) 58(4):174–175.
   PubMedGoogle Scholar
• CHAPPELL PB, LECKMAN JF, SCAHILL LD, HARDIN MT, ANDERSON G, COHEN DJ: Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's syndrome: a pilot study. Psychiatry Res. (1993) 47(3):267–280.
   PubMedGoogle Scholar
• MCCONVILLE BJ, NORMAN AB, FOGELSON MH, ERENBERG G: Sequential use of opioid antagonists and agonists in Tourette's syndrome. Lancet (1994) 343(8897):601.
   PubMedGoogle Scholar
• ••
   Google Scholar
• GOLDSTEIN JA: Nifedipine treatment of Tourette's syndrome. I Clin. Psychiatry (1984) 45(8):360.
   PubMedGoogle Scholar
• BERG R: A case of Tourette syndrome treated with nifedipine. Acta. Psychiati: Scand. (1985) 72(4):400–401.
   PubMedGoogle Scholar
• WALSH TL, LAVENSTEIN B, LICAMELE WL, BRONHEIM S, O'LEARY J: Calcium antagonists in the treatment of Tourette's disorder. Am. Psychiatry (1986) 143(11):1467–1468.
   PubMed Web of Science ®Google Scholar
• MICHELI F, GATTO M, LEKHUNIEC E et al.: Treatment of Tourette's syndrome with calcium antagonists. Clin. Neuropharmacol (1990) 13(1):77–83.
   PubMedGoogle Scholar
• ALESSI NE, WALDEN ME, HSIEH PS: Nifedipine augments haloperidol in the treatment of Tourette syndrome. Pediati: Neurol (1988) 4(3):191.
   PubMedGoogle Scholar
• ALESSI NE, WALDEN M, HSIEH PS: Nifedipine-haloperidol combination in the treatment of Gilles de la Tourette's syndrome: a case study. Clin. Psychiatry (1989) 50(3):103–104.
   PubMedGoogle Scholar
• TOREN P, LAOR N, COHEN DJ, WOLMER L, WEIZMAN A: Ondansetron treatment in patients with Tourette's syndrome. Int. Gin. Psychopharmacol (1999) 14(6):373–376.
   PubMedGoogle Scholar
• BONNIER C, NASSOGNE MC, EVRARD P: Ketanserin treatment of Tourette's syndrome in children. Am. Psychiatry (1999) 156(7):1122–1123.
   PubMed Web of Science ®Google Scholar
• CATH DC, GIJSMAN HJ, SCHOEMAKER RC et al.: The effect of m-CPP on tics and obsessive-compulsive phenomena in Gilles de la Tourette syndrome. Psychopharmacology OHL. (1999) 144(2):137–143.
   PubMedGoogle Scholar
• DURSUN SM, BURKE JG, REVELEY MA: Buspirone treatment of Tourette's syndrome. Lancet (1995) 345(8961):1366–1367.
   PubMedGoogle Scholar
• FEIGIN A, KURLAN R, MCDERMOTT MP et al.: A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder. Neurology (1996) 46(4):965–968.
   PubMed Web of Science ®Google Scholar
• PETERSON BS, ZHANG H, ANDERSON GM, LECKMAN JF: A double-blind, placebo-controlled, crossover trial of an antiandrogen in the treatment of Tourette's syndrome. Clin. Psychopharmacol (1998) 18(4):324–331.
   PubMedGoogle Scholar
• PETERSON BS, LECKMAN JF, SCAHILL L et al.: Steroid hormones and Tourette's syndrome: early experience with antiandrogen therapy. j. Clin. Psychopharmacol (1994) 14(2):131–135.
   PubMedGoogle Scholar
• HOOPES SP: Donepezil for Tourette's disorder and ADHD. I Clin. Psychopharmacol (1999) 19(4):381–382.
   Google Scholar
• ROJAS VM, DAVIES RK: Reserpine treatment of comorbid Tourette's disorder and tardive dystonia. I Gin. Psychiatry (1999) 60(10):709–710.
   Google Scholar
• ABUZZAHAB FS, BROWN VL: Control of Tourette's syndrome with topiramate. Am. J. Psychiatry (2001) 158(6):968.
   PubMedGoogle Scholar
• RAUCH SL, BAER L, COS GROVE GR, JENIKE MA: Neurosurgical treatment of Tourette's syndrome: a critical review. Compr Psychiatry (1995) 36(2):141–156.
   PubMed Web of Science ®Google Scholar
• •An excellent systematic review of neurosurgical treatment of TS, concluding that it is still experimental.
   Google Scholar
• BABEL TB, WARNKE PC, OSTERTAG CB: Immediate and long term outcome after infrathalamic and thalamic lesioning for intractable Tourette's syndrome. J. Neura. Neurosurg. Psychiatry(2001) 70(5):666–671.
   PubMedGoogle Scholar
• KORZENEV AV, SHOUSTIN VA, ANICHKOV AD, POLONSKIY JZ, NIZKOVOLOS VB, OBLYAPIN AV: Differential approach to psychosurgery of obsessive disorders. Stereotact. Funct. Neurosurg. (1997) 68(1–4 Pt 1):226–230.
   Google Scholar
• VANDEWALLE V, VAN DER LINDEN C, GROENEWEGEN HJ, CAEMAERT J: Stereotactic treatment of Gilles de la Tourette syndrome by high frequency stimulation of thalamus. Lancet (1999) 353(9154):724.
   PubMed Web of Science ®Google Scholar
• PIACENTINI J, CHANG S: Behavioral treatments for Tourette syndrome and tic disorders: state of the art. Adv. Nemo]. (2001) 85:319–331.
   PubMedGoogle Scholar
• •A comprehensive review of behavioural treatments for TS.
   Google Scholar
• BERGIN A, WARANCH HR, BROWN J, CARSON K, SINGER HS: Relaxation therapy in Tourette syndrome: a pilot study. Pediatr. Nemo]. (1998) 18(2):136–142.
   Google Scholar
• AZRIN NH, PETERSON AL: Habit reversal for the treatment of Tourette syndrome. Behav. Res. The]: (1988) 26(4):347–351.
   PubMed Web of Science ®Google Scholar
• PETERSON AL, AZRIN NH: An evaluation of behavioral treatments for Tourette syndrome. Behav. Res. Ther. (1992) 30(2):167–174.
   PubMedGoogle Scholar
• ROBERTSON MM, EAPEN V: Pharmacologic controversy of CNS stimulants in Gilles de la Tourette's syndrome. Gin. Neuropharmacol (1992) 15(5):408–425.
   PubMedGoogle Scholar
• MTA COLLABORATIVE GROUP: Moderators and mediators of treatment response for children with attention-deficit/ hyperactivity disorder: the Multimodal Treatment Study of Children with ADHD. Arch. Gen. Psychiatry (1999) 56(12):1088–1096.
   PubMedGoogle Scholar
• MTA COLLABORATIVE GROUP: A 14-month randomized clinical trial of treatment strategies for attention-deficit/ hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch. Gen. Psychiatry (1999) 56(12):1073–1086.
   PubMedGoogle Scholar
• POLLACK MA, COHEN NL, FRIEDHOFF AJ: Gilles de la Tourette's syndrome. Familial occurrence and precipitation by methylphenidate therapy. Arch. Neurol (1977) 34(10):630–632.
   Google Scholar
• GOLDEN GS: The effect of central nervous system stimulants on Tourette syndrome. Ann. Neurol (1977) 2(1):69–70.
   PubMedGoogle Scholar
• LOWE TL, COHEN DJ, DETLOR J, KREMENITZER MW, SHAYWITZ BA: Stimulant medications precipitate Tourette's syndrome. JAMA (1982) 247(12):1729–1731.
   PubMed Web of Science ®Google Scholar
• GADOW KD, SVERD J, SPRAFKIN J, NOLAN EE, GROSSMAN S: Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch. Gen. Psychiatry(1999) 56(4):330–366.
   PubMed Web of Science ®Google Scholar
• LAW SF, SCHACHAR RJ: Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder?' Am. Acad. Child Adolesc. Psychiatry (1999) 38(8):944–951.
   PubMed Web of Science ®Google Scholar
• THE TOURETTE'S SYNDROME STUDY GROUP: Treatment of ADHD in children with tics: a randomized controlled trial. Neurology (2002) 58(4):527–536.
   Google Scholar
• ••A well-designed study investigating theefficacy of donidine and methylphenidate, alone and in combination, on ADHD in children with comorbid tics. According to this study both drugs (particularly in combination) are effective. Most importantly, no significant exacerbation of tics by methylphenidate was seen. 194. CONNOR DF, FLETCHER KE, SWANSON JM: A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. I Am. Acad. Child. Adolesc. Psychiatry (1999) 38(12):1551–1559.
   Google Scholar
• •A meta-analysis of 11 studies of clonidine for ADHD showed that clonidine is less effective than stimulants and often associated with side effects.
   Google Scholar
• NASS R, BRESSMAN S: Attention deficit hyperactivity disorder and Tourette syndrome: what's the best treatment? Neurology(2002) 58(4):513–514.
   PubMedGoogle Scholar
• EAPEN V, ROBERTSON MM: Comorbid obsessive-compulsive disorder and Tourette syndrome. CNS Drugs (2000) 13(3):173–183.
   Google Scholar
• •A good review of pharmacotherapy of associated OCB in TS.
   Google Scholar
• ROBERTSON MM: Self-injurious behavior and Tourette syndrome. Adv. Neurol. (1992) 58:105–114.
   PubMedGoogle Scholar
• •An excellent summary of all aspects of SIB in TS.
   Google Scholar
• ROBERTSON MM, TRIMBLE MR, LEES AJ: Self-injurious behaviour and the Gilles de la Tourette syndrome: a clinical study and review of the literature. Psycho]. Merl (1989) 19(3):611–625.
   PubMedGoogle Scholar
• ROBERTSON M, DORAN M, TRIMBLE M, LEES AJ: The treatment of Gilles de la Tourette syndrome by limbic leucotomy. Neurol. Neurosurg. Psychiatry (1990) 53(8):691–694. zoo. HAMILTON CS, GARVEY MA, SWEDO SE: Therapeutic implications of immunology for tics and obsessive- compulsive disorder. Adv. Neurol. (2001) 85:311–318.
   Google Scholar
• •In this summary of therapeutic implications of immunology for tics and OCD it is concluded that neither irmrtunomodulatory treatment nor antibiotic prophylaxis are currently indicated in the clinical care of children with TS.
   Google Scholar
• RIDDLE MA, HARDIN MT, TOWBIN KE, LECKMAN JF, COHEN DJ: Tardive dyskinesia following haloperidol treatment in Tourette's syndrome. Arch. Gen. Psychiatry (1987) 44(1):98–99.
   PubMed Web of Science ®Google Scholar
• GOLDEN GS: Tardive dyskinesia in Tourette syndrome. Pediatr. Neurol. (1985) 1(3):192–194.
   PubMedGoogle Scholar
• CAINE ED, POLINSKY RJ: Tardive dyskinesia in persons with Gilles de la Tourette's disease. Arch. Neurol. (1981) 38(7):471–472.
   PubMedGoogle Scholar
• MIZRAHI EM, HOLTZMAN D, THARP B: Haloperidol-induced tardive dyskinesia in a child with Gilles de la Tourette's disease. Arch. Neurol. (1980) 37(12):780. zos. CAINE ED, MARGOLIN DI, BROWN GL, EBERT MH: Gilles de la Tourette's syndrome, tardive dyskinesia, and psychosis in an adolescent. Am. J. Psychiatry (1978) 135(2):241–243. zos. EAPEN V, KATONA CLE, BARNES TRE, ROBERTSON MM: Sulpiride-induced tardive dyskinesia in a person with Gilles de la Tourette's syndrome. J. Pschopharmacol (1993) 7:290–292.
   Google Scholar
• SILVA R, MAGEE H, FRIEDHOFF A: Persistent tardive dyskinesia and other neuroleptic-related dyskinesias inTourette's disorder. I Child. Adolesc. Psychopharmacol. (1995) 3:137-144. zos. SINGH SK, JANKOVIC J: Tardive dystonia in patients with Tourette's syndrome. Mov. Disord. (1988) 3(3):274–280. zos. SHAPIRO AK, SHAPIRO E: Clinical efficacy of haloperidol, pimozide, penfluridol, and clonidine in the treatment of tourette syndrome. Adv. Neurol. (1982) 35:383–386.
   Google Scholar
• COMINGS DE: Tardive dyskinesia. In: Tourette Syndrome and Human Behavior: Comings DE (ed.), Hope Press, Duarte, CA, USA (1990):557–559.
   Google Scholar
• •A critical review of different aspects of tardive dyskinesia after nettroleptic treatment indicating that this adverse effect is rare in TS patients.
   Google Scholar